中国人群食管鳞癌生存分析研究新进展

doi:10.11904/j.issn.1002-3070.2018.04.012

摘要/Abstract

摘要： 我国食管癌整体负担较重,鳞癌是我国食管癌最主要的病理类型,占比超过85%。当前我国食管癌人群生存率的研究存在诸多局限,需要以人群为基础的多中心大样本研究来提供属于我国食管鳞癌生存率等预后指标的信息,验证国外已有证据并在中国发现新特征。人群为基础的高精度生存分析能提供代表性的生存率结果,反映某一地区食管癌整体预后水平,为制定和优化食管癌防治策略提供可靠依据;也可为探索和验证影响食管癌治疗效果的潜在因素提供代表性资料,从而进一步优化临床治疗策略。本文总结了近年来我国在食管癌生存率、预后因素等方面的研究进展,并与国际进行比较,以期为后续研究提供依据。

关键词: 食管癌, 鳞状细胞癌, 生存率, 预后, 中国

Abstract: The overall burden of esophageal cancer in China is still relatively serious.Esophageal squamous cell carcinoma(ESCC)is the most important pathological type of esophageal cancer in China,accounting for more than 85%.At present,there are still many limitations on the study of the survival rate of esophageal cancer in China.It is necessary to provide information on the prognostic indicators such as the survival rate of ESCC in China based on the multi-center large-sample study to verify the existing evidence abroad and discover new features in China.The population based high-precision survival analysis can provide representative survival results,reflecting the overall prognosis of esophageal cancer in a certain area and also supply a reliable basis for the development and optimization of esophageal cancer prevention and treatment strategies.This analysis can also explore and verify the effects of esophageal cancer treatment to underly factors which provide representative material to further optimize clinical treatment strategies.This article summarizes the research progress in the survival rate and prognosis factors of esophageal cancer in China in recent years,and compares it with the international other countries,in order to provide a basis for follow-up research.

Key words: Esophageal cancer, Squamous cell carcinoma, Survival rate, Prognosis, China

中图分类号:

R735.1

杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.

DU Lingbin,WEI Wenqiang. Progress research in survival analysis of esophageal squamous cell carcinoma(ESCC)in Chinese population[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 344-348.

参考文献

1 Ervik M,LamF,Ferlay J.et al.Cancer Today[DB/OL].Lyon:International Agency for Research on Cancer,2016.
2 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
3 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
4 Howlader N,Noone AM,Krapcho M,et al.SEER cancer statistics review,1975-2014[DB/OL].USA:National Cancer Institute,2017.
5 Bohanes P,Yang D,Chhibar RS,et al.Influence of sex on the survival of patients with esophageal cancer[J].J Clin Oncol,2012,30(18):2265-2272.
6 赫捷,陈万青.2016中国肿瘤登记年报[M].北京:清华大学出版社,2017.
7 Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
8 Compton CC,Byrd DR,Garcia-Aguilar J,et al.Cancer survival analysis[M].New York:Springer,2012.
9 Bissonnette L,Hurd MD,Michaud PC.Individual survival curves comparing subjective and observed mortality risks[J].Health Econ,2017,26(12):285-303.
10 左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639-642.
11 Okuyama A,Shibata A,Nishimoto H.Critical points for interpreting patients' survival rate using cancer registries:a literature review[J].J Epidemiol,2018,28(2):61-66.
12 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
13 Allemani C,Weir HK,Carreira H,et al.Global surveillance of cancer survival 1995-2009:analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J].Lancet,2015,385(9972):977-1010.
14 The Surveillance,Epidemiology,End Results(SEER)Program.Cancer stat facts:esophageal cancer[DB/OL].USA:National Cancer Institute,2017.
15 Zeng C,Wen W,Morgans AK,et al.Disparities by race,age,and sex in the improvement of survival for major cancers:results from the National Cancer Institute Surveillance,Epidemiology,and End Results(SEER)program in the United States,1990 to 2010[J].JAMA Oncol,2015,1(1):88-96.
16 Anderson LA,Tavilla A,Brenner H,et al.Survival for oesophageal,stomach and small intestine cancers in Europe 1999-2007:results from EUROCARE-5[J].Eur J Cancer,2015,51(15):2144-2157.
17 Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
18 臧豹,赵建强,侯予龙.食管癌淋巴结转移数量与生存率的相关性[J].中华实用诊断与治疗杂志,2016,30(9):900-901.
19 李国栋.1510例食管癌患者术后生存率及预后影响因素分析[D].太原:山西医科大学,2016.
20 李学民,汤萨,彭秀青,等.1973-2005年手术治疗食管癌患者5年生存率变化分析[J].肿瘤防治研究,2014,41(3):237-242.
21 Wang J,Wu N,Zheng QF,et al.Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma[J].World J Gastroenterol,2014,20(48):18397-18403.
22 Offman J,Pesola F,Sasieni P.Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037[J].Br J Cancer,2018,118(10):1391-1398.
23 Siewert JR,Ott K.Are squamous and adenocarcinomas of the esophagus the same disease?[J].Semin Radiat Oncol,2007,17(1):38-44.
24 Ilson DH,Ajani J,Bhalla K,et al.Phase II trial of paclitaxel,fluorouracil,and cisplatin in patients with advanced carcinoma of the esophagus[J].J Clin Oncol,1998,16(5):1826-1834.
25 Rizk NP,Venkatraman E,Bains MS,et al.American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma[J].J Clin Oncol,2007,25(5):507-512.
26 Rizk N,Venkatraman E,Park B,et al.The prognostic importance of the number of involved lymph nodes in esophageal cancer:implications for revisions of the American Joint Committee on Cancer staging system[J].J Thorac Cardiovasc Surg,2006,132(6):1374-1381.
27 Kattan MW,Hess KR,Amin MB,et al.American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine[J].CA Cancer J Clin,2016,66(5):370-374.
28 Rice TW,Gress DM,Patil DT,et al.Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(4):304-317.
29 Lin WC,Ding YF,Hsu HL,et al.Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma[J].Cancer,2017,123(20):3904-3915.
30 Xi M,Xu C,Liao Z,et al.Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer:a retrospective,single-institutional analysis[J].Int J Radiat Oncol Biol Phys,2017,99(3):667-676.
31 Merkow RP,Bilimoria KY,Keswani RN,et al.Treatment trends,risk of lymph node metastasis,and outcomes for localized esophageal cancer[J].J Natl Cancer Inst,2014,106(7):1-8.
32 方文涛.通过食管癌TNM新分期(第八版)解读2017年NCCN食管鳞癌诊疗指南[J].中华胃肠外科杂志,2017,10(20):1122-1126.
33 Strong VE,D'amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66.
34 王澜,李晓旭,韩春,等.食管癌长期生存患者临床特征及治疗相关因素分析[J].中华放射肿瘤学杂志,2016,25(6):565-570.
35 景奇,陈诗奉.新辅助化疗联合手术与单纯手术治疗食管癌疗效及安全性Meta分析[J].重庆医学,2011,40(32):3236-3238.
36 刘爱娜,黄镜,蔡锐刚,等.138例晚期食管癌的化疗疗效和预后因素分析[J].癌症,2008,27(4):400-406.
37 Raja SG,Salhiyyah K,Nagarajan K.Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer?[J].Interact Cardiovasc Thorac Surg,2007,6(5):661-664.
38 Kim YC,Park KO,Choi IS,et al.A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma[J].Korean J Int Med,1996,11(1):50-57.
39 Shimada H,Nabeya Y,Okazumi S,et al.Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma[J].Surgery,2003,133(5):486-494.
40 Lagarde SM,Ten Kate FJ,Richel DJ,et al.Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction[J].Ann Surg Oncol,2007,14(2):977-991.
41 Markar SR,Mackenzie H,Lagergren P,et al.Surgeon age in relation to prognosis after esophageal cancer resection[J].Ann Surg,2017,4(265):639-643.
42 Thrift AP,Nagle CM,Fahey PP,et al.The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival[J].Int J Cancer,2012,131(5):759-768.
43 Li XC,Wang M,Yang M,et al.A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma[J].Ann Oncol,2018,29(4):938-944.
44 Xia Y,Li YH,Chen Y,et al.A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma[J].Int J Clin Oncol,2018,23(3):458-465.
45 Wu N,Zhu Y,Kadel D,et al.The prognostic influence of body mass index,resting energy expenditure and fasting blood glucose on postoperative patients with esophageal cancer[J].BMC Gastroenterol,2016,16(1):142-153.
46 Boshier PR,Ziff C,Adam ME,et al.Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer:a systematic review and meta-analysis[J].Dis Esophagus,2017,4(31):1-10.
47 Revels SL,Morris AM,Reddy RM,et al.Racial disparities in esophageal cancer outcomes[J].Ann Surg Oncol,2013,20(4):1136-1141.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	刘仲阳, 袁欣, 周文, 李晓亮, 樊立茂. 微创小切口手术对早期胸中下段食管癌患者的治疗效果及对其疼痛的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 57-61.
[11]	王蕾, 姜寰宇, 宋凯镔. miR-219调控PRKCI表达在舌鳞状细胞癌中作用和机制[J]. 实用肿瘤学杂志, 2018, 32(6): 510-514.
[12]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[13]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[14]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[15]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.